阿立派唑联合米氮平治疗躯体形式障碍患者的临床疗效及安全性研究

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Aripiprazole combined with Mirtazapine in the treatment of somatoform disorders.Methods A total of 100 patients with somatoform disorders admitted to the Third People′s Hospital of Ganzhou City from June 2019 to March 2020 were selected as the research subjects.By drawing lots method,they were divided into a control group and an observation group,with 50 cases in each group.In the control group,Mirtazapine was used,and in the observation group,Aripiprazole combined with Mirtazapine was added.The disease condition,psychological state,and clinical side effect before and after treatment in the two groups were compared.Results There were no statistically significant differences between the two groups in the severity of disease and psychological state before treatment (P＞0.05).The self-rating symptom scale (SCL-90) score of the observation group eight weeks after treatment was (74.32±8.24) points,lower than that of the control group of (100.24±10.15) points,and the difference was statistically significant (P＜0.05).The Hamilton anxiety scale (HAMA) score eight weeks after treatment was (13.52±1.26) points in the observation group,lower than that in the control group of (20.12±1.45) points,and the Hamilton depression scale(HAMD) score was (14.08±1.32) points,lower than that in the control group of (21.27±1.60) points,the differences were statistically significant (P＜0.05).Thereatment emergent symptom scale (TESS) scores of patients in the observation group at 2,8 weeks after treatment ([30.12±1.24],[12.32±1.27]points) were lower than those of the control group([48.27±2.15],[25.48±2.65]points),the differences were statistically significant (P＜0.05).Conclusion The combination of Aripiprazole and Mirtazapine for patients with somatoform disorders can reduce the severity of the disease,alleviate negative emotions,reduce the adverse effect after medication,and has high promotion and application value.

Key words： Aripiprazole Mirtazapine Somatoform disorder Severity of symptoms Adverse effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Wen-ting
	LAI Yan
	LIAO Mei-rong
	LAI Zhong-hong
	XIAO Feng

Cite this article:

CAI Wen-ting,LAI Yan,LIAO Mei-rong, et al. Clinical efficacy and safety study of Aripiprazole combined with Mirtazapine in the treatment of patients with somatoform disorders[J]. 中国当代医药, 2020, 27(35): 82-85.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I35/82

[1]	王芸，王高华，王惠玲，等.躯体形式障碍患者注意偏向与躯体症状的关联[J].中国临床心理学杂志，2019，27（1）：14-17.
[2]	魏镜，李涛，罗夏红.躯体症状障碍诊断标准及可操作性研究现状[J].中华精神科杂志，2019，52（4）：235-240.
[3]	张禹，张佳蕾.基于SCL-90量表的妇幼医院护士心理健康状况调查[J].中华现代护理杂志，2019，25（15）：1951-1954.
[4]	胡承平，秦虹云，朱娜.社区轻度认知功能障碍老年人焦虑抑郁情绪及躯体疼痛对睡眠的影响研究[J].精神医学杂志，2018，31（6）：450-455.
[5]	石洲宝.安神胶囊治疗精神分裂症患者睡眠障碍临床研究[J].西部中医药，2017，30（3）：5-8.
[6]	单建华，孙菡，罗新.引导式教育训练对长期住院精神分裂症患者的影响[J].西部中医药，2018，31（8）：120-123.
[7]	曾奕彬，胡号应，葛鑫宇.涤痰化瘀理神汤治疗精神分裂症的效果及对患者体质的影响[J].西部中医药，2020，33（7）：86-88.
[8]	王芸，王高华，王惠玲，等.躯体形式障碍患者注意偏向与躯体症状的关联[J].中国临床心理学杂志，2019，27（1）：14-17.
[9]	杨颖，费才莲.青年女性躯体形式障碍并发头痛1例的临床护理[J].现代医药卫生，2018，34（17）：2767-2768.
[10]	汪西莹，李江波.躯体形式障碍患者疼痛症状与注意偏向的关系[J].中国心理卫生杂志，2017，11（4）：22.
[11]	易峰，蒋幸衍，甄莉丽，等.躯体形式障碍患者心智理论特征及与焦虑情绪的相关性研究[J].中国医师杂志，2017，19（5）：734-736.
[12]	程毅.米氮平合并认知行为疗法治疗躯体形式障碍的疗效[J].中国健康心理学杂志，2016，24（11）：1612-1614.
[13]	蒋胜菊.米氮平、舍曲林、度洛西汀在治疗伴躯体疼痛症状抑郁症患者中的临床疗效[J].医学理论与实践，2019，22（15）：14-15.
[14]	平丽慧，祁继鹏.度洛西汀肠溶片联合米氮平并辅以认知行为疗法治疗躯体形式障碍的临床观察[J].北方药学，2019，16（1）：74-75.
[15]	王静.三种抗抑郁症药物治疗伴躯体疼痛症状的抑郁症患者的对比研究[J].中国实用医药，2016，11（27）：8-10.
[16]	裴丽粉.度洛西汀和米氮平治疗老年抑郁症的临床分析[J].大家健康旬刊，2017，11（3）：22-23.
[17]	袁思华，聂悦康.简析米氮平辅助治疗精神分裂症阴性症状的疗效与安全性[J].中国医药指南，2019，17（22）：158-159.
[18]	陈坤城.阿立哌唑与奥氮平治疗精神分裂症的疗效及对糖脂代谢的影响评价[J].医药前沿，2016，6（8）：214-215.
[19]	雷秀萍，郭燕，赵玲丹.牛黄宁宫片联合阿立哌唑治疗精神分裂症的效果[J].中国医药导报，2019，16（31）：123-126.
[20]	陈钱芳，沈志华.阿立哌唑联合认知干预对精神分裂症患者认知功能及生活质量的影响[J].中国现代医生，2019，57（2）：77-80.